Wissenschaftliche Arbeiten

Doç. Dr. Deniz Işık

94 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Quelle: OpenAlex

  3. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  5. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  7. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  8. Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020553 PMID 41598493 Frei zugänglicher VolltextQuelle: OpenAlex

  9. Clinical Outcomes of Stage IS Non-seminomatous Germ Cell Testicular Tumors: Single-Center Experience

    Istanbul Medical Journal, 2026

    DOI 10.4274/imj.galenos.2026.62829 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041671 PMID 41753358 Frei zugänglicher VolltextQuelle: OpenAlex

  11. 657eP Time toxicity of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: A real-world comparative study of palbociclib and ribociclib

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107673 Quelle: OpenAlex

  12. Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62061004 PMID 42356017 Frei zugänglicher VolltextQuelle: OpenAlex

  13. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Frei zugänglicher VolltextQuelle: OpenAlex

  14. Prognostic Factors and Survival in Thymoma and Thymic Carcinoma: A Retrospective Cohort Study

    Cerrahpasa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26089 Frei zugänglicher VolltextQuelle: OpenAlex

  15. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001717 PMID 40162996 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61061075 PMID 40572762 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  17. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  19. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  20. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  21. Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions

    Cureus, 2025

    DOI 10.7759/cureus.78076 PMID 39872919 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  22. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  23. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

    Journal of Personalized Medicine, 2025

    DOI 10.3390/jpm16010008 PMID 41590501 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  24. The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

    Medicina, 2025

    DOI 10.3390/medicina61101813 PMID 41155800 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm15010247 PMID 41517497 Frei zugänglicher VolltextQuelle: OpenAlex

  26. Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

    Breast Cancer Research and Treatment, 2025

    DOI 10.1007/s10549-025-07694-7 PMID 40214840 2 Zitationen (Europe PMC) Quelle: OpenAlex

  27. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    Medicina, 2025

    DOI 10.3390/medicina61071161 PMID 40731791 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  29. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

    Pharmaceuticals, 2025

    DOI 10.3390/ph18060931 PMID 40573326 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  31. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32090503 PMID 41002573 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  32. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Frei zugänglicher VolltextQuelle: OpenAlex

  33. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

    Cancers, 2025

    DOI 10.3390/cancers17071076 PMID 40227569 Frei zugänglicher VolltextQuelle: OpenAlex

  34. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

    Healthcare, 2025

    DOI 10.3390/healthcare13151810 PMID 40805843 Frei zugänglicher VolltextQuelle: OpenAlex

  35. Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25030 Frei zugänglicher VolltextQuelle: OpenAlex

  36. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2025.2601938 PMID 41414901 Quelle: OpenAlex

  37. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  38. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  39. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  40. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  41. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 Zitationen (Europe PMC) Quelle: OpenAlex

  42. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  43. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  44. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  45. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

    Medicina, 2024

    DOI 10.3390/medicina60071088 PMID 39064516 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  46. Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

    Medicina, 2024

    DOI 10.3390/medicina60122069 PMID 39768949 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  47. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

    Cureus, 2024

    DOI 10.7759/cureus.63362 PMID 39070363 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  48. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

    Medicina, 2024

    DOI 10.3390/medicina60060951 PMID 38929568 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  49. A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

    Cancer Medicine, 2024

    DOI 10.1002/cam4.70002 PMID 39030808 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  50. Male breast cancer in a single-center experience: Diagnosis, clinicopathological features, and treatment strategies

    Northern Clinics of Istanbul, 2024

    DOI 10.14744/nci.2024.32815 PMID 39431041 Frei zugänglicher VolltextQuelle: OpenAlex